Use este identificador para citar ou linkar para este item: http://repositorio.ufla.br/jspui/handle/1/45619
Título : COVID-19 update: the race to therapeutic development
Autor: Twomey, Julianne D.
Luo, Shen
Dean, Alexis Q.
Bozza, William P.
Nalli, Ancy
Zhang, Baolin
Palavras-chave: COVID-19
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Virus life cycle
Therapeutic targets
Drug development
Antivirals
Immunomodulators
Monoclonal antibodies
Angiotensin-converting enzyme 2 (ACE2)
Spike protein
Publicador: Elsevier
Data da publicação: Dez-2020
Referência: TWOMEY, J. D. et al. COVID-19 update: the race to therapeutic development. Drug Resistance Updates, [S.l.], v. 53, Dec. 2020.
Abstract: The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), represents an unprecedented challenge to global public health. At the time of this review, COVID-19 has been diagnosed in over 40 million cases and associated with 1.1 million deaths worldwide. Current management strategies for COVID-19 are largely supportive, and while there are more than 2000 interventional clinical trials registered with the U.S. National Library of Medicine (clinicaltrials.gov), results that can clarify benefits and risks of candidate therapies are only gradually becoming available. We herein describe recent advances in understanding SARS-CoV-2 pathobiology and potential therapeutic targets that are involved in viral entry into host cells, viral spread in the body, and the subsequent COVID-19 progression. We highlight two major lines of therapeutic strategies for COVID-19 treatment: 1) repurposing the existing drugs for use in COVID-19 patients, such as antiviral medications (e.g., remdesivir) and immunomodulators (e.g., dexamethasone) which were previously approved for other disease conditions, and 2) novel biological products that are designed to target specific molecules that are involved in SARS-CoV-2 viral entry, including neutralizing antibodies against the spike protein of SARS-CoV-2, such as REGN-COV2 (an antibody cocktail), as well as recombinant human soluble ACE2 protein to counteract SARS-CoV-2 binding to the transmembrane ACE2 receptor in target cells. Finally, we discuss potential drug resistance mechanisms and provide thoughts regarding clinical trial design to address the diversity in COVID-19 clinical manifestation. Of note, preventive vaccines, cell and gene therapies are not within the scope of the current review.
URI: https://www.sciencedirect.com/science/article/pii/S1368764620300637
http://repositorio.ufla.br/jspui/handle/1/45619
Idioma: en_US
Aparece nas coleções:FCS - Artigos sobre Coronavirus Disease 2019 (COVID-19)

Arquivos associados a este item:
Não existem arquivos associados a este item.


Os itens no repositório estão protegidos por copyright, com todos os direitos reservados, salvo quando é indicado o contrário.